Diagnostic and Therapeutic Insights into Pediatric Neurosarcoidosis: Observations from French Pediatric Rheumatology Centers

Racha Tohme,Anca Tanase,Cécile Dumaine,Perrine Dusser,Homa Adle-Biassette,Veronique Despert,Albert Faye,Inès Mannes,Isabelle Melki,Isabelle Kone-Paut,Ulrich Meinzer
DOI: https://doi.org/10.1016/j.pediatrneurol.2024.10.007
IF: 4.21
2024-10-20
Pediatric Neurology
Abstract:Background The diagnosis and management of neurosarcoidosis in pediatric patients present significant challenges, with few documented cases available to guide health care providers. Existing reports focus mainly on the initial manifestations. Our aim was to describe the clinical presentation, management and medium-term evolution of neurosarcoidosis in children. Methods In this retrospective, multi-centric, observational study we collected data from pediatric patients followed in French pediatric rheumatology centers with a diagnosis of neurosarcoidosis between January 2001 and June 2023. Results We identified 11 patients diagnosed with neurosarcoidosis, comprising 8 girls and 3 boys. The mean age at diagnosis of sarcoidosis was 10 [5-15] years and the mean age of diagnosis of NS was 11.5 [5-17] years. Predominant neurological symptoms included headache (9/11 patients), papilledema (6/11 patients), facial palsy in 2 patients, seizures in one patient and motor deficit in two patients. 9/11 patients had eye involvement, which consisted of granulomatous, bilateral uveitis. All patients exhibited meningitis, with CSF white blood cell counts ranging from 6 to 70 cells/mm 3 . Six individuals presented neurological abnormalities on imaging, detailed in this study. The main treatment regimen involved corticosteroids, methotrexate and TNF-alpha inhibitors. Biologics targeting TNF-alpha were necessary to achieve remission in 8/11 patients. In two patients who did not receive this treatment initially, it was required later in the course of evolution. Conclusions This study contributes to the comprehension of the clinical course of NS in pediatric populations and reinforces the recommendation for the early consideration of biologics targeting TNF-alpha in children with NS.
pediatrics,clinical neurology
What problem does this paper attempt to address?